{"id":50024,"date":"2025-12-05T22:28:24","date_gmt":"2025-12-05T14:28:24","guid":{"rendered":"https:\/\/flcube.com\/?p=50024"},"modified":"2025-12-05T22:28:25","modified_gmt":"2025-12-05T14:28:25","slug":"formosa-pharma-app13007-clobetasol-asean-deal-with-rxilient","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50024","title":{"rendered":"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient"},"content":{"rendered":"\n<p><strong>Formosa Pharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6838:TPE\">TPE: 6838<\/a>) announced an exclusive licensing agreement with <strong>Rxilient Medical Pte. Ltd.<\/strong>, granting exclusive rights to commercialize <strong>clobetasol propionate ophthalmic suspension 0.05% (APP13007)<\/strong> in key ASEAN regions: Indonesia, Philippines, Singapore, and Thailand.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-licensing-agreement-amp-territory\">Licensing Agreement &amp; Territory<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Formosa Pharmaceuticals, Inc. (TPE: 6838)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Rxilient Medical Pte. Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>APP13007 (clobetasol propionate ophthalmic suspension 0.05%)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Indonesia, Philippines, Singapore, Thailand (ASEAN)<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive commercialization rights<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>APNT nanoparticle formulation platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-clinical-advantages\">Product Profile &amp; Clinical Advantages<\/h2>\n\n\n\n<p><strong>Active Ingredient:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clobetasol propionate<\/strong>: Superpotent corticosteroid for rapid anti-inflammatory action<\/li>\n<\/ul>\n\n\n\n<p><strong>APNT Nanoparticle Platform:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enables superior ocular penetration and sustained drug release<\/li>\n\n\n\n<li>Reduces dosing frequency while maintaining efficacy<\/li>\n<\/ul>\n\n\n\n<p><strong>Dosing Regimen:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Twice daily for 14 days<\/strong> (vs. competitive products requiring more frequent administration)<\/li>\n\n\n\n<li><strong>Patient convenience<\/strong>: Simple, short course of therapy<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Benefits:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid relief<\/strong>: Onset of action within 24-48 hours<\/li>\n\n\n\n<li><strong>Sustained effect<\/strong>: Continued anti-inflammatory action post-treatment<\/li>\n\n\n\n<li><strong>Approved<\/strong>: US FDA approval in 2024 validates safety and efficacy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-commercial-opportunity\">Market Context &amp; Commercial Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>Population<\/th><th>Ophthalmic Inflammation Prevalence<\/th><th>Market Potential<\/th><\/tr><\/thead><tbody><tr><td><strong>Indonesia<\/strong><\/td><td>275 million<\/td><td>High (tropical climate, infection rates)<\/td><td><strong>$15-20M<\/strong> peak sales<\/td><\/tr><tr><td><strong>Philippines<\/strong><\/td><td>110 million<\/td><td>Moderate-high<\/td><td><strong>$8-12M<\/strong> peak sales<\/td><\/tr><tr><td><strong>Singapore<\/strong><\/td><td>5.5 million<\/td><td>Developed market, premium pricing<\/td><td><strong>$5-8M<\/strong> peak sales<\/td><\/tr><tr><td><strong>Thailand<\/strong><\/td><td>70 million<\/td><td>Growing ophthalmology sector<\/td><td><strong>$10-15M<\/strong> peak sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Total ASEAN Opportunity<\/strong>: <strong>$38-55 million<\/strong> peak sales potential for APP13007<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-competitive-position\">Strategic Outlook &amp; Competitive Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage<\/strong>: First superpotent corticosteroid with 14-day, BID regimen in ASEAN<\/li>\n\n\n\n<li><strong>Rxilient&#8217;s Edge<\/strong>: Established ophthalmology distribution network across Southeast Asia<\/li>\n\n\n\n<li><strong>Formosa&#8217;s Strategy<\/strong>: Capitalizes on US FDA approval to accelerate ex-US partnerships<\/li>\n\n\n\n<li><strong>Revenue Model<\/strong>: Upfront payment + milestones + double-digit royalties; Formosa retains manufacturing<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration, and revenue projections for APP13007 in ASEAN markets. Actual results may differ due to regulatory, competitive, and reimbursement uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50026,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1419,44,4489,1418],"class_list":["post-50024","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-formosa-pharmaceuticals","tag-ophthalmology","tag-rxilient-medical","tag-tpe-6838"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd., granting exclusive rights to commercialize clobetasol propionate ophthalmic suspension 0.05% (APP13007) in key ASEAN regions: Indonesia, Philippines, Singapore, and Thailand.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50024\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient\" \/>\n<meta property=\"og:description\" content=\"Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd., granting exclusive rights to commercialize clobetasol propionate ophthalmic suspension 0.05% (APP13007) in key ASEAN regions: Indonesia, Philippines, Singapore, and Thailand.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50024\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-05T14:28:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-05T14:28:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient\",\"datePublished\":\"2025-12-05T14:28:24+00:00\",\"dateModified\":\"2025-12-05T14:28:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0501.webp\",\"keywords\":[\"Formosa Pharmaceuticals\",\"Ophthalmology\",\"Rxilient Medical\",\"TPE: 6838\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50024#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50024\",\"name\":\"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0501.webp\",\"datePublished\":\"2025-12-05T14:28:24+00:00\",\"dateModified\":\"2025-12-05T14:28:25+00:00\",\"description\":\"Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd., granting exclusive rights to commercialize clobetasol propionate ophthalmic suspension 0.05% (APP13007) in key ASEAN regions: Indonesia, Philippines, Singapore, and Thailand.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50024\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50024#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient - Insight, China&#039;s Pharmaceutical Industry","description":"Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd., granting exclusive rights to commercialize clobetasol propionate ophthalmic suspension 0.05% (APP13007) in key ASEAN regions: Indonesia, Philippines, Singapore, and Thailand.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50024","og_locale":"en_US","og_type":"article","og_title":"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient","og_description":"Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd., granting exclusive rights to commercialize clobetasol propionate ophthalmic suspension 0.05% (APP13007) in key ASEAN regions: Indonesia, Philippines, Singapore, and Thailand.","og_url":"https:\/\/flcube.com\/?p=50024","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-05T14:28:24+00:00","article_modified_time":"2025-12-05T14:28:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50024#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50024"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient","datePublished":"2025-12-05T14:28:24+00:00","dateModified":"2025-12-05T14:28:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50024"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50024#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0501.webp","keywords":["Formosa Pharmaceuticals","Ophthalmology","Rxilient Medical","TPE: 6838"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50024#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50024","url":"https:\/\/flcube.com\/?p=50024","name":"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50024#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50024#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0501.webp","datePublished":"2025-12-05T14:28:24+00:00","dateModified":"2025-12-05T14:28:25+00:00","description":"Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd., granting exclusive rights to commercialize clobetasol propionate ophthalmic suspension 0.05% (APP13007) in key ASEAN regions: Indonesia, Philippines, Singapore, and Thailand.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50024#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50024"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50024#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0501.webp","width":1080,"height":608,"caption":"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50024#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50024"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50024\/revisions"}],"predecessor-version":[{"id":50027,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50024\/revisions\/50027"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50026"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}